-
2
-
-
75749108918
-
Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis
-
Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010; 340:b5569.
-
(2010)
BMJ.
, vol.340
, pp. b5569
-
-
Parsons, A.1
Daley, A.2
Begh, R.3
Aveyard, P.4
-
3
-
-
84859771379
-
Molecular mechanisms of cisplatin resistance
-
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31:1869-1883.
-
(2012)
Oncogene.
, vol.31
, pp. 1869-1883
-
-
Galluzzi, L.1
Senovilla, L.2
Vitale, I.3
Michels, J.4
Martins, I.5
Kepp, O.6
Castedo, M.7
Kroemer, G.8
-
4
-
-
84923071009
-
The role of DNA repair pathways in cisplatin resistant lung cancer
-
The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treat Rev. 2014; 40:1161-1170.
-
(2014)
Cancer Treat Rev
, vol.40
, pp. 1161-1170
-
-
-
5
-
-
0029067343
-
Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells
-
Lai SL, Hwang J, Perng RP, Whang-Peng J. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. Oncology Res. 1995; 7:31-38.
-
(1995)
Oncology Res.
, vol.7
, pp. 31-38
-
-
Lai, S.L.1
Hwang, J.2
Perng, R.P.3
Whang-Peng, J.4
-
6
-
-
0036890375
-
DNA repair and cisplatin resistance in non-small-cell lung cancer
-
Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002; 38:217-227.
-
(2002)
Lung Cancer.
, vol.38
, pp. 217-227
-
-
Rosell, R.1
Lord, R.V.2
Taron, M.3
Reguart, N.4
-
7
-
-
84875163620
-
Cisplatin resistance associated with PARP hyperactivation
-
Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Orear C, Lissa D, Sukkurwala AQ, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 2013; 73:2271-2280.
-
(2013)
Cancer Res.
, vol.73
, pp. 2271-2280
-
-
Michels, J.1
Vitale, I.2
Galluzzi, L.3
Adam, J.4
Olaussen, K.A.5
Kepp, O.6
Senovilla, L.7
Talhaoui, I.8
Guegan, J.9
Enot, D.P.10
Talbot, M.11
Robin, A.12
Girard, P.13
Orear, C.14
Lissa, D.15
Sukkurwala, A.Q.16
-
8
-
-
84875926116
-
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
-
Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis. 2013; 34:739-749.
-
(2013)
Carcinogenesis.
, vol.34
, pp. 739-749
-
-
Cheng, H.1
Zhang, Z.2
Borczuk, A.3
Powell, C.A.4
Balajee, A.S.5
Lieberman, H.B.6
Halmos, B.7
-
9
-
-
80052442469
-
Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy
-
Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, Batzler AJ, Jenkins GD, Abo RP, Li L, Cunningham JM, Sun Z, Yang P, Wang L. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res. 2011; 17:5801-5811.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 5801-5811
-
-
Tan, X.L.1
Moyer, A.M.2
Fridley, B.L.3
Schaid, D.J.4
Niu, N.5
Batzler, A.J.6
Jenkins, G.D.7
Abo, R.P.8
Li, L.9
Cunningham, J.M.10
Sun, Z.11
Yang, P.12
Wang, L.13
-
11
-
-
36849017497
-
IL-6 involvement in epithelial cancers
-
Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest. 2007; 117:3660-3663.
-
(2007)
J Clin Invest.
, vol.117
, pp. 3660-3663
-
-
Schafer, Z.T.1
Brugge, J.S.2
-
12
-
-
84886002334
-
Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance
-
Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, Stanger BZ, Chung I, Rhim AD, di Magliano MP. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 2013; 73:6359-6374.
-
(2013)
Cancer Res.
, vol.73
, pp. 6359-6374
-
-
Zhang, Y.1
Yan, W.2
Collins, M.A.3
Bednar, F.4
Rakshit, S.5
Zetter, B.R.6
Stanger, B.Z.7
Chung, I.8
Rhim, A.D.9
di Magliano, M.P.10
-
13
-
-
27744468499
-
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer
-
Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res. 2005; 11:7674-7682.
-
(2005)
Clin Cancer Res.
, vol.11
, pp. 7674-7682
-
-
Dalwadi, H.1
Krysan, K.2
Heuze-Vourc'h, N.3
Dohadwala, M.4
Elashoff, D.5
Sharma, S.6
Cacalano, N.7
Lichtenstein, A.8
Dubinett, S.9
-
14
-
-
36849012237
-
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
-
Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 2007; 117:3846-3856.
-
(2007)
J Clin Invest.
, vol.117
, pp. 3846-3856
-
-
Gao, S.P.1
Mark, K.G.2
Leslie, K.3
Pao, W.4
Motoi, N.5
Gerald, W.L.6
Travis, W.D.7
Bornmann, W.8
Veach, D.9
Clarkson, B.10
Bromberg, J.F.11
-
15
-
-
0029074945
-
Serum levels of interleukin 6 in patients with lung cancer
-
Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 1995; 71:1095-1098.
-
(1995)
Br J Cancer.
, vol.71
, pp. 1095-1098
-
-
Yanagawa, H.1
Sone, S.2
Takahashi, Y.3
Haku, T.4
Yano, S.5
Shinohara, T.6
Ogura, T.7
-
16
-
-
4344598656
-
Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer
-
Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, Motohashi S, Yokoi S, Hiroshima K, Tagawa M, Nakayama T, Fujisawa T. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother. 2004; 53:786-792.
-
(2004)
Cancer Immunol Immunother.
, vol.53
, pp. 786-792
-
-
Yamaji, H.1
Iizasa, T.2
Koh, E.3
Suzuki, M.4
Otsuji, M.5
Chang, H.6
Motohashi, S.7
Yokoi, S.8
Hiroshima, K.9
Tagawa, M.10
Nakayama, T.11
Fujisawa, T.12
-
17
-
-
84874109197
-
Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy
-
Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, Chen CJ, Hsiung CA, Su WC. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer. 2013; 132:1977-1985.
-
(2013)
Int J Cancer.
, vol.132
, pp. 1977-1985
-
-
Chang, C.H.1
Hsiao, C.F.2
Yeh, Y.M.3
Chang, G.C.4
Tsai, Y.H.5
Chen, Y.M.6
Huang, M.S.7
Chen, H.L.8
Li, Y.J.9
Yang, P.C.10
Chen, C.J.11
Hsiung, C.A.12
Su, W.C.13
-
18
-
-
0142250392
-
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence
-
Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003; 9:4653-4665.
-
(2003)
Clin Cancer Res.
, vol.9
, pp. 4653-4665
-
-
Trikha, M.1
Corringham, R.2
Klein, B.3
Rossi, J.F.4
-
19
-
-
77949485931
-
CD133 and non-small-cell lung cancer
-
author reply 988-989
-
Wiwanitkit V. CD133 and non-small-cell lung cancer. Eur J Cardiothorac Surg. 2010; 37:988. author reply 988-989.
-
(2010)
Eur J Cardiothorac Surg.
, vol.37
, pp. 988
-
-
Wiwanitkit, V.1
-
20
-
-
84882700957
-
Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling
-
Lu L, Li C, Li D, Wang Y, Zhou C, Shao W, Peng J, You Y, Zhang X, Shen X. Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling. Mol Cell Biochem. 2013; 381:273-282.
-
(2013)
Mol Cell Biochem.
, vol.381
, pp. 273-282
-
-
Lu, L.1
Li, C.2
Li, D.3
Wang, Y.4
Zhou, C.5
Shao, W.6
Peng, J.7
You, Y.8
Zhang, X.9
Shen, X.10
-
21
-
-
84875757507
-
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells
-
Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG, Weiss S. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro-oncology. 2013; 15:198-207.
-
(2013)
Neuro-oncology.
, vol.15
, pp. 198-207
-
-
Stechishin, O.D.1
Luchman, H.A.2
Ruan, Y.3
Blough, M.D.4
Nguyen, S.A.5
Kelly, J.J.6
Cairncross, J.G.7
Weiss, S.8
-
22
-
-
84891520098
-
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
-
Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff M, Tu AW, Fan AC, et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 2013; 122:2864-2876.
-
(2013)
Blood.
, vol.122
, pp. 2864-2876
-
-
Beurlet, S.1
Omidvar, N.2
Gorombei, P.3
Krief, P.4
Le Pogam, C.5
Setterblad, N.6
de la Grange, P.7
Leboeuf, C.8
Janin, A.9
Noguera, M.E.10
Hervatin, F.11
Sarda-Mantel, L.12
Konopleva, M.13
Andreeff, M.14
Tu, A.W.15
Fan, A.C.16
-
23
-
-
0033600235
-
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
-
Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 1999; 399:814-817.
-
(1999)
Nature.
, vol.399
, pp. 814-817
-
-
Yuan, Z.M.1
Shioya, H.2
Ishiko, T.3
Sun, X.4
Gu, J.5
Huang, Y.Y.6
Lu, H.7
Kharbanda, S.8
Weichselbaum, R.9
Kufe, D.10
-
24
-
-
0030667522
-
Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways
-
Barlow C, Brown KD, Deng CX, Tagle DA, Wynshaw-Boris A. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet. 1997; 17:453-456.
-
(1997)
Nat Genet.
, vol.17
, pp. 453-456
-
-
Barlow, C.1
Brown, K.D.2
Deng, C.X.3
Tagle, D.A.4
Wynshaw-Boris, A.5
-
25
-
-
33748435058
-
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
-
Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355:983-991.
-
(2006)
N Engl J Med.
, vol.355
, pp. 983-991
-
-
Olaussen, K.A.1
Dunant, A.2
Fouret, P.3
Brambilla, E.4
Andre, F.5
Haddad, V.6
Taranchon, E.7
Filipits, M.8
Pirker, R.9
Popper, H.H.10
Stahel, R.11
Sabatier, L.12
Pignon, J.P.13
Tursz, T.14
Le Chevalier, T.15
Soria, J.C.16
-
26
-
-
40249094603
-
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer
-
Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, Suehisa H, Kobayashi N, Aoe M, Yoshino T, Kiura K, Date H. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer. 2008; 59:377-384.
-
(2008)
Lung Cancer.
, vol.59
, pp. 377-384
-
-
Fujii, T.1
Toyooka, S.2
Ichimura, K.3
Fujiwara, Y.4
Hotta, K.5
Soh, J.6
Suehisa, H.7
Kobayashi, N.8
Aoe, M.9
Yoshino, T.10
Kiura, K.11
Date, H.12
-
27
-
-
12144285914
-
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients
-
Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A, Spanish Lung Cancer G. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2004; 10:1318-1325.
-
(2004)
Clin Cancer Res.
, vol.10
, pp. 1318-1325
-
-
Rosell, R.1
Danenberg, K.D.2
Alberola, V.3
Bepler, G.4
Sanchez, J.J.5
Camps, C.6
Provencio, M.7
Isla, D.8
Taron, M.9
Diz, P.10
Artal, A.11
Spanish Lung Cancer, G.12
-
28
-
-
39649113108
-
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival
-
Wegiel B, Bjartell A, Culig Z, Persson JL. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer. 2008; 122:1521-1529.
-
(2008)
Int J Cancer.
, vol.122
, pp. 1521-1529
-
-
Wegiel, B.1
Bjartell, A.2
Culig, Z.3
Persson, J.L.4
-
29
-
-
0037443661
-
Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3
-
Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, Rossaint R, Heinrich PC, Muller-Newen G. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol. 2003; 170:3263-3272.
-
(2003)
J Immunol.
, vol.170
, pp. 3263-3272
-
-
Niemand, C.1
Nimmesgern, A.2
Haan, S.3
Fischer, P.4
Schaper, F.5
Rossaint, R.6
Heinrich, P.C.7
Muller-Newen, G.8
-
30
-
-
77950923924
-
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer
-
Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010; 24:837-852.
-
(2010)
Genes Dev.
, vol.24
, pp. 837-852
-
-
Oliver, T.G.1
Mercer, K.L.2
Sayles, L.C.3
Burke, J.R.4
Mendus, D.5
Lovejoy, K.S.6
Cheng, M.H.7
Subramanian, A.8
Mu, D.9
Powers, S.10
Crowley, D.11
Bronson, R.T.12
Whittaker, C.A.13
Bhutkar, A.14
Lippard, S.J.15
Golub, T.16
-
31
-
-
84860346143
-
Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment
-
Hsieh JL, Lu CS, Huang CL, Shieh GS, Su BH, Su YC, Lee CH, Chang MY, Wu CL, Shiau AL. Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment. Cancer Lett. 2012; 321:36-44.
-
(2012)
Cancer Lett.
, vol.321
, pp. 36-44
-
-
Hsieh, J.L.1
Lu, C.S.2
Huang, C.L.3
Shieh, G.S.4
Su, B.H.5
Su, Y.C.6
Lee, C.H.7
Chang, M.Y.8
Wu, C.L.9
Shiau, A.L.10
-
32
-
-
0031744116
-
Emergence of higher levels of invasive and metastatic properties in the drug resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice
-
Mitsumoto M, Kamura T, Kobayashi H, Sonoda T, Kaku T, Nakano H. Emergence of higher levels of invasive and metastatic properties in the drug resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice. J Cancer Res Clin Oncol. 1998; 124:607-614.
-
(1998)
J Cancer Res Clin Oncol.
, vol.124
, pp. 607-614
-
-
Mitsumoto, M.1
Kamura, T.2
Kobayashi, H.3
Sonoda, T.4
Kaku, T.5
Nakano, H.6
-
33
-
-
84872530707
-
Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature
-
Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One. 2013; 8:e54193.
-
(2013)
PLoS One.
, vol.8
-
-
Barr, M.P.1
Gray, S.G.2
Hoffmann, A.C.3
Hilger, R.A.4
Thomale, J.5
O'Flaherty, J.D.6
Fennell, D.A.7
Richard, D.8
O'Leary, J.J.9
O'Byrne, K.J.10
-
34
-
-
85018181524
-
Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption
-
Lin ZZ, Chou CH, Cheng AL, Liu WL, Chia-Hsien Cheng J. Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption. Int J Cancer. 2013.
-
(2013)
Int J Cancer
-
-
Lin, Z.Z.1
Chou, C.H.2
Cheng, A.L.3
Liu, W.L.4
Chia-Hsien Cheng, J.5
-
35
-
-
33846821915
-
p53-deficientcells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage
-
Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficientcells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell. 2007; 11:175-189.
-
(2007)
Cancer Cell.
, vol.11
, pp. 175-189
-
-
Reinhardt, H.C.1
Aslanian, A.S.2
Lees, J.A.3
Yaffe, M.B.4
-
36
-
-
84862779596
-
Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma
-
Lu YS, Chou CH, Tzen KY, Gao M, Cheng AL, Kulp SK, Cheng JC. Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma.Int J Radiat Oncol Biol Phys. 2012; 83:e181-189.
-
(2012)
Int J Radiat Oncol Biol Phys
, vol.83
, pp. e181-e189
-
-
Lu, Y.S.1
Chou, C.H.2
Tzen, K.Y.3
Gao, M.4
Cheng, A.L.5
Kulp, S.K.6
Cheng, J.C.7
-
37
-
-
45549104364
-
p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK
-
Boehme KA, Kulikov R, Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci U S A. 2008; 105:7785-7790.
-
(2008)
Proc Natl Acad Sci U S A.
, vol.105
, pp. 7785-7790
-
-
Boehme, K.A.1
Kulikov, R.2
Blattner, C.3
-
38
-
-
20044390541
-
Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM
-
Viniegra JG, Martinez N, Modirassari P, Hernandez Losa J, Parada Cobo C, Sanchez-Arevalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, Ramon y Cajal S, Rojas JM, Sanchez-Prieto R. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem. 2005; 280:4029-4036.
-
(2005)
J Biol Chem.
, vol.280
, pp. 4029-4036
-
-
Viniegra, J.G.1
Martinez, N.2
Modirassari, P.3
Hernandez Losa, J.4
Parada Cobo, C.5
Sanchez-Arevalo Lobo, V.J.6
Aceves Luquero, C.I.7
Alvarez-Vallina, L.8
Ramon y Cajal, S.9
Rojas, J.M.10
Sanchez-Prieto, R.11
-
39
-
-
0036829397
-
Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened
-
Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002; 16:2743-2748.
-
(2002)
Genes Dev.
, vol.16
, pp. 2743-2748
-
-
Chen, J.K.1
Taipale, J.2
Cooper, M.K.3
Beachy, P.A.4
-
40
-
-
61549142050
-
Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line
-
Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY. Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Human Immunol. 2009; 70:151-158.
-
(2009)
Human Immunol.
, vol.70
, pp. 151-158
-
-
Li, Y.Y.1
Hsieh, L.L.2
Tang, R.P.3
Liao, S.K.4
Yeh, K.Y.5
-
41
-
-
0024382959
-
Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6
-
discussion 386-377
-
Podor TJ, Jirik FR, Loskutoff DJ, Carson DA, Lotz M. Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann New York Acad Sci. 1989; 557:374-385. discussion 386-377.
-
(1989)
Ann New York Acad Sci.
, vol.557
, pp. 374-385
-
-
Podor, T.J.1
Jirik, F.R.2
Loskutoff, D.J.3
Carson, D.A.4
Lotz, M.5
-
42
-
-
84906814857
-
IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer
-
Sun X, Mao Y, Wang J, Zu L, Hao M, Cheng G, Qu Q, Cui D, Keller ET, Chen X, Shen K, Wang J. IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene. 2014; doi: 10.1038/onc.2014.158
-
(2014)
Oncogene
-
-
Sun, X.1
Mao, Y.2
Wang, J.3
Zu, L.4
Hao, M.5
Cheng, G.6
Qu, Q.7
Cui, D.8
Keller, E.T.9
Chen, X.10
Shen, K.11
Wang, J.12
-
43
-
-
84909987265
-
Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation
-
Yan HQ, Huang XB, Ke SZ, Jiang YN, Zhang YH, Wang YN, Li J, Gao FG. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation. Cancer Sci. 2014; 105:1220-1227.
-
(2014)
Cancer Sci.
, vol.105
, pp. 1220-1227
-
-
Yan, H.Q.1
Huang, X.B.2
Ke, S.Z.3
Jiang, Y.N.4
Zhang, Y.H.5
Wang, Y.N.6
Li, J.7
Gao, F.G.8
-
44
-
-
26844545448
-
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
-
Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer. 2005; 4:25.
-
(2005)
Mol Cancer.
, vol.4
, pp. 25
-
-
Wu, C.1
Wangpaichitr, M.2
Feun, L.3
Kuo, M.T.4
Robles, C.5
Lampidis, T.6
Savaraj, N.7
-
45
-
-
84908461196
-
Strategic targeting of the PI3K-NFkappaB axis in cisplatin-resistant NSCLC
-
Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K. Strategic targeting of the PI3K-NFkappaB axis in cisplatin-resistant NSCLC. Cancer Biol Ther. 2014; 15:1367-1377.
-
(2014)
Cancer Biol Ther.
, vol.15
, pp. 1367-1377
-
-
Heavey, S.1
Godwin, P.2
Baird, A.M.3
Barr, M.P.4
Umezawa, K.5
Cuffe, S.6
Finn, S.P.7
O'Byrne, K.J.8
Gately, K.9
-
46
-
-
33646435805
-
Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer
-
Andriani F, Perego P, Carenini N, Sozzi G, Roz L. Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer. Neoplasia. 2006; 8:9-17.
-
(2006)
Neoplasia.
, vol.8
, pp. 9-17
-
-
Andriani, F.1
Perego, P.2
Carenini, N.3
Sozzi, G.4
Roz, L.5
-
47
-
-
79952539094
-
Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549)
-
Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011; 30:20.
-
(2011)
J Exp Clin Cancer Res.
, vol.30
, pp. 20
-
-
Bian, H.B.1
Pan, X.2
Yang, J.S.3
Wang, Z.X.4
De, W.5
|